In different diseases, C3 is activated through distinct pathways—predominantly via the alternative pathway in ANCA-associated vasculitis, characterized by prominent local synthesis and deposition, whereas in SLE the classical pathway is the major driver, leading to systemic complement consumption [206,207]. This evidence concerns the gene C3 and systemic lupus erythematosus.